| INTRODUCTION
Within the context of pharmacy practice, during the last 2 decades, increased attention has been focused on the change in the community pharmacist's role from product-focused to more patient-focused activities. With continued efforts to improve patient health outcomes, and in response to the challenge of a patient-focused approach, the concept of pharmaceutical care was developed in the United States 1 and was quickly adopted as "good pharmacy practice" internationally. 2 Delivery of pharmaceutical care has important demands on structure and process of the delivery of services in community pharmacies. 3 Different countries, according to the country-specific practice culture and systems of health delivery, have adopted pharmaceutical care services in different forms that match the local situation needs and which take into account various barriers and facilitating factors. 3 The concept of pharmaceutical care is complex and has continued to evolve over the years with many different definitions appearing in the literature. In an attempt to harmonize definitions, the board of the Pharmaceutical Care Network Europe (PCNE) reached a consensus on a PCNE definition of pharmaceutical care, stating that it "is the pharmacist's contribution to the care of individuals in order to optimise medicines use and improve health outcomes." 4 A number of barriers have been identified internationally, which have hindered the implementation of comprehensive pharmaceutical care programmes within community pharmacies, including limited time,
lack of reimbursement for the extra time required to deliver the service, high work load, inadequate competency, and lack of commitment. [5] [6] [7] [8] To facilitate the implementation of pharmaceutical care in the community pharmacy setting, there is a need to build good relationships with general medical practitioners (GPs), to receive financial compensation for the service, to have the appropriate premises (eg, private counselling area),
to have appropriate and sufficiently trained staff, to have a high degree of co-ordinated teamwork and an ability to receive external guidance. 9 A conscious effort from individual pharmacists to deliver pharmaceutical care programmes and/or legislation that redefines the role the pharmacist is required to facilitate pharmaceutical care implementation. 10 Although the effectiveness of pharmaceutical care delivery has been largely defined in the context of research studies, 11 quantification of the service provided under everyday care conditions is important. A few studies describe the influence of the policy context in the implementation of services, 12 while others focus on structural influences, such as the existence of software capable of uploading identified drug-related problems into a national database. 13 The usual method to assess the provision of pharmaceutical care deployed in a large number of pharmacies is by the use of survey methodology, using a validated data collection instrument. Survey methodology compromises much of the pharmacy practice research literature corpus; it is surprising, however, that only a relatively few studies have assessed the degree of provision of pharmaceutical care in community pharmacies. 10, [14] [15] [16] [17] [18] [19] [20] [21] The main aim of the present study was to assess the current degree of provision of pharmaceutical care by community pharmacists across Europe and to determine whether the degree of implementation had changed since 2006.
| METHODS
The provision of pharmaceutical care by community pharmacists across Europe was assessed through the co-operation of the PCNE (www.
pcne.org). Having achieved the agreement of PCNE members from different European countries to participate, data were collected from 16 countries (Bosnia, Denmark, England, Germany, Italy, Lithuania, Malta, Moldova, the Netherlands, Northern Ireland, Norway, Portugal, Serbia, Spain, Sweden, and Switzerland), with ethical approval being achieved as required by local regulation. Belgium and the Ukraine engaged with the initiative, but due to logistical reasons, data collection/validation was delayed and has not been included in the analysis.
| Questionnaire/instrument
A validated instrument, with 2 separate sections, was used. 10, 14 Section A collected data on pharmacists' demographics and pharmacy services and layout. Section B evaluated the types of services provided to the last patients using the pharmacy (5 or 10) referring to a specific time period (2 or 6 wk) using vignettes from a slightly modified version of the Behavioural Pharmaceutical Care Scale (BPCS 
| Data collection
The study was coordinated by Queen's University Belfast and used PCNE to identify country coordinators. The country coordinators were responsible for determining the most effective manner to reach one pharmacist per pharmacy (ie, pharmacist most involved in patient care activities), and they were informed on the sample size considered representative of their country, considering a confidence interval of 95%, a 3% error, and a prevalence of the phenomenon (provision of pharmaceutical care) ranging from 4.8% to 25%, according to results from the previous study. 10 In countries that had not participated in the previous round, the lowest prevalence was considered, unless a national study could be used as reference (eg, Spain). The method of distribution varied from country to country according to the available resources and research practice, ie, online, face-to-face, or via regular post. Most countries used an online survey method (Table 1 ).
| Data entry and analysis
Data entry was the responsibility of each country coordinator, guided by a standard operating procedure to ensure quality. 22 The responding community pharmacists were more commonly (>50%) females in all of the surveyed countries except Italy, the Netherlands, and Northern Ireland. Pharmacies had been instructed that the pharmacist with the most patient contact should take the lead in the survey, resulting in >60% of responding pharmacists with more than 5 years of experience in community pharmacy in all surveyed countries.
| Variations in pharmacy practice settings
A wide distribution in the type and location of the pharmacies was noted in the surveyed countries. Pharmacy type ranged from 100% independent in Denmark, Germany, and Spain to 89.6% large multiple in Serbia and 90.3% in Norway (Table 2) .
It was common for one full-time equivalent (FTE) pharmacist to work in each pharmacy in England, Malta, the Netherlands, and Northern Ireland whereas the remainder of the surveyed countries had 2 or more pharmacists working in each pharmacy. In Sweden, 46% of the respondents were "prescriptionists," holding a BSc (Pharm) degree, while the remainder were pharmacists with an MSc (Pharm) degree.
In all of the surveyed countries (except in Denmark, Germany, Norway, Serbia, and Switzerland), there was, on average, 2 or fewer dispensing support staff working in the pharmacies. In half of the surveyed countries, the pharmacies on average dispensed >200 prescription items per day, while <200 items per day were dispensed in Bosnia, Germany, Table 2) . 
| BPCS scores
The BPCS scores for each country are presented in Table 3 . In the Netherlands survey, one of the items in the questionnaire from the referral and consultation dimension was inadvertently missed out; it was therefore not possible to calculate this dimension score and the total BPCS score for this country.
The highest mean total BPCS scores were achieved by pharma- Referral and consultation activity scores achieved in Spain were significantly higher (P < .05) than in other countries.
The highest mean instrumental activity dimension score was noted in the Netherlands (26.6/35), while again the lowest score was achieved in Moldova (17.3/35). Instrumental activity scores achieved in the Netherlands were significantly (P < .05) higher than in the other surveyed countries.
| Providers and non-providers of pharmaceutical care
In accordance with the original questionnaire designers, 14 at country level, pharmacies achieving BPCS scores within the top 25% were considered providers of pharmaceutical care while those in the bottom 25% were considered non-providers (Table 4) . data were noted for the instrumental activity scores (Table 5) . (Table 6) . 
| Evolution of pharmaceutical care provision over time

| Response rate
The response rate to a questionnaire is an important issue, as a low rate can increase the risk of bias in the answers received. 24 The response rate varied from 1.6% in Spain (but since 346 pharmacies participated, the sample exceeded the minimum estimated sample size required) to 99.0% in Bosnia. The differences in the response rates between countries can be attributed to the different survey distribution methodology used (online, postal, or face-to-face interview) as well as the variable involvement of national organisations able to motivate response. However, more important than the sample size is its representativeness, assessed by how number of responses compares with national data. On this aspect, it should be noted that the presence of selection bias cannot be disregarded for Sweden, judging by the proportion of pharmacists versus prescriptionists among the respondents, compared to their proportions within the community pharmacy work force. In addition, a much lower response rate was achieved in 
| Provision of pharmaceutical care
The present study showed that the mean score for the community pharmacists across the surveyed European countries was 69. Lack of time and resources has repeatedly been found as the main reasons for the lack of provision of comprehensive pharmaceutical care in the community pharmacy setting internationally. 5, 6, 9, 25 Other studies have suggested that lack of commitment among pharmacy practitioners to pharmaceutical care is a major barrier for The Netherlands are not included in the table because the overall score could not be calculated.
implementation. 8 Although not specifically examined in the present study, it is likely that these remain major barriers. In addition, due to the variability between results for individual pharmacies within each country, the present findings indicate a lack of standardized policies and/or procedures for the delivery of pharmaceutical care.
To promote a more patient centred approach to pharmacy practice, hscni.net/services/1944.htm). In Portugal, pharmacists have been remunerated for the provision of additional services to patients with diabetes. 26 A system for the documentation of medication-related problems has been available in all community pharmacies in Sweden. 3, 13 Reimbursement for certain elements of pharmaceutical care has been agreed in the Netherlands, Switzerland, Germany, and in Great Britain. 27 To promote best practice, the Royal Pharmaceutical Society of Great Britain has launched an early adopter programme that specifically addressed "keeping patients safe when they transfer between care providers" with a focus on medicines management across interfaces.
28
Such early adopter programmes, in which pioneer pharmacists initially provide and refine new care delivery approaches, promote the application of new care models into routine practice. 29 However, when compared with the results reported in the 2006 survey, 10 the mean total BPCS scores improved for several countries.
Although differing response rates may have been at least in part responsible for the improvements in some countries, the results seem highly plausible. For instance, in Portugal, the fact that pharmaceutical care has been legally recognized in 2007 cannot be disregarded. 30 Moreover, in Switzerland, the introduction of remunerated medicines use review in 2010 is very likely to have driven the observed increase. 31 In Germany, the development of a nationwide service in medication review was launched in 2011; since then, 2 main studies have been rolled out, the Arzneimittelinitiative Sachsen-Thüringen (ARMIN) study, which runs in 2 states and is being remunerated (www.arzneimittelinitiative.de) and the Arzneimitteltherapiesicherheit in Apotheken (ATHINA) study, which currently is still not remunerated. 32 The sharp increase observed in Denmark also seems consistent with data reported elsewhere, influenced by various ongoing projects. 33 In general, direct patient care activity scores were higher in the present study, while the referral and consultation activities decreased 
| Providers versus non-providers of pharmaceutical care
The present study showed that the percentage of respondents who were judged to be providers of pharmaceutical care, using the methodology suggested by Odedina and colleagues 14 (top 25% of BPCS scores), was less than those deemed non-providers (bottom 25% of BPCS scores) in the European countries.
Pharmaceutical care is of course not a service delivered by a pharmacist in isolation from other health care professions. Participation in multidisciplinary meetings can help build professional relationships and help in the initiation of discussions about different patient cases.
This type of activity has also been documented as a facilitator to pharmaceutical care, with a particular emphasis on relationships with physicians. 9 In addition, pharmaceutical care delivery is expected to be enhanced when related services such as health screening, patient monitoring, medication review, and health promotion/education are delivered within the pharmacy. This association was noted in both the present study and the 2006 study. The importance of appropriate software cannot be overemphasized, as this can aid in the decision making and in the documentation of different services. Access to medical notes/clinical information is of paramount importance in the delivery of comprehensive pharmaceutical care, and limited access to patient medical details has been identified by others as a barrier to the provision of pharmaceutical care. 25 Findings from the present study (having a postgraduate qualification in pharmacy and a high number prescription items dispensed in an average day) were also highlighted as facilitators to pharmaceutical care provision in a US study. 16 This latter study found that the predictors for pharmaceutical care service provision included pharmacists holding a postgraduate qualification, the pharmacy being located in a clinic, the pharmacy being independent, and a high number of prescriptions dispensed per day. 16 It should be acknowledged that the slow evolution in the provision of pharmaceutical care is unlikely to change without significant intervention at the system level (eg, new community pharmacy contracts), with adequate remuneration for patient-centred services. Gathering evidence at the national level, coupled with lobbying activities, should be influential in changing policy, ultimately leading to improved practice.
| Limitations
The different survey methodology approaches, coupled with low response rates achieved in a number of countries, represent the major limitation of this study indicating that results may not be generalizable, due to a likely selection bias. Furthermore, the provision of pharmaceutical care was self-reported and self-rated, which may lead to over reporting of good practice initiatives.
| CONCLUSIONS
The present study demonstrated the evolution in self-reported provi- 
